Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. United States Pharmacovigilance Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4)
5.2.2. By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
5.2.3. By Service Provider (In-House, Contract Outsourcing)
5.2.4. By End User (Hospitals, Research Organizations, Industries)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. North-East Pharmacovigilance Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Clinical Trial Phase
6.2.2. By Method
6.2.3. By Service Provider
6.2.4. By End User
7. Mid-West Pharmacovigilance Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Clinical Trial Phase
7.2.2. By Method
7.2.3. By Service Provider
7.2.4. By End User
8. West Pharmacovigilance Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Clinical Trial Phase
8.2.2. By Method
8.2.3. By Service Provider
8.2.4. By End User
9. South Pharmacovigilance Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Clinical Trial Phase
9.2.2. By Method
9.2.3. By Service Provider
9.2.4. By End User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Development
11.2. Mergers & Acquisitions
11.3. Product Launches
12. Policy & Regulatory Landscape
13. United States Economic Profile
14. United States Pharmacovigilance Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. F. Hoffmann-La Roche & Co.
16.1.1. Business Overview
16.1.2. Product Offerings
16.1.3. Recent Developments
16.1.4. Financials (As Reported)
16.1.5. Key Personnel
16.2. Laboratory Corporation of America Holdings
16.3. IBM Corporation
16.4. United BioSource Corporation
16.5. BioClinica Inc.
16.6. Novatis Corporation
16.7. ArisGlobal LLC
16.8. Cognizant Technology Solutions Corp
16.9. Accenture Inc.
16.10. Capgemini US LLC
17. Strategic Recommendations
18. About Us & Disclaimer